Influenza vaccine

Phase 3Vaccine

Novartis

Influenza vaccine is one of 313 small molecule programs targeting Sarcoidosis. It is currently in Phase 3.

Indications

106

Total Trials

Active Trials

312

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcoidosisActive, not recruiting

Hepatitis BActive, not recruiting

Metabolic SyndromeActive, not recruiting

Mood DisorderActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Heart DiseaseActive, not recruiting

ElderlyCompleted

Colorectal CancerNot yet recruiting

InfluenzaCompleted

SarcoidosisPreclinical

Active, not recruiting

Hepatitis BPreclinical

Active, not recruiting

Metabolic SyndromePreclinical

Active, not recruiting

Mood DisorderPreclinical

Active, not recruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Obstructive Sleep ApneaPreclinical

Active, not recruiting

Heart DiseasePreclinical

Active, not recruiting

ElderlyPreclinical

Completed

Colorectal CancerPhase 2

Not yet recruiting

InfluenzaPhase 3

Completed

Showing 10 of 11 indications

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Telisotuzumab Adizutecan

AbbVie

Phase 3

2 2

TAS 102

Taiho Oncology, Inc.

Phase 3

8 3

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

4 4

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

3 5

Influenza vaccine

Novartis

Phase 3

1 6

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 7

Biological Check-up

UUniversity Hospital, Bordeaux

Phase 3

1 8

Thymosin Alpha1

SSun Yat-sen University

Phase 3

1 9

Folfirinox

PPhanes Therapeutics

Phase 3

1 10

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Influenza

NCT06355232

Q4 2027

Recruiting

Immune Response

NCT03323112

Post-ApprovalRecruiting

Inflammatory Response

NCT06336317

Q3 2028

Phase 2Not yet recruiting

Colorectal Cancer

NCT05909423

Q1 2029

N/ARecruiting

Acute Coronary Syndrome

NCT07259252

Clinical

Trials by Indication[1]

Influenza71 trials

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

Completed·UUniversity of Wisconsin, Madison··NCT04531787·139 enrolled

Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel

Completed·AAbt Associates··NCT03331991·2,400 enrolled

Plant Stanol Esters and Influenza Vaccination

Completed·MMaastricht University Medical Center·N/A·NCT05706350·137 enrolled

Show 68 more trials

Influenza Vaccine Post Allogeneic Transplant

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01215981·68 enrolled

Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination

Completed·FFundación Pública Andaluza Progreso y Salud·Phase 3·NCT01761435·499 enrolled

Study to Evaluate Safety, Tolerability and Immunogenicity of a Bedside Mixing Combination of Two Adjuvanted Influenza Vaccines

Completed· Novartis logo

Novartis·Phase 1·NCT00735020·72 enrolled

Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Completed·RResearch Institute for Biological Safety Problems·Phase 1·NCT03028116·44 enrolled

Influenza Vaccine in Lung Transplant Patients

Completed·UUniversity of Wisconsin, Madison··NCT00205270·126 enrolled

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

Completed· Novartis logo

Novartis·Phase 2·NCT00408395·281 enrolled

Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine

Completed·WWashington University School of Medicine·Phase 1·NCT03748524·11 enrolled

Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine

Completed· GSK logo

GSK·Phase 3·NCT00197223·6,213 enrolled

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT05091307·861 enrolled

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Completed·UUniversity of Wisconsin, Madison··NCT04530786·100 enrolled

Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression

Unknown status·UUniversity of Texas at Austin·Phase 4·NCT03756246·75 enrolled

Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults

Completed·AArcturus Therapeutics, Inc.·Phase 3·NCT06279871·1,514 enrolled

Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

Completed· Novartis logo

Novartis·Phase 2·NCT00316628·50 enrolled

Agaricus Bisporus and Influenza Vaccination Response

Completed·MMaastricht University Medical Center·N/A·NCT06041867·88 enrolled

Tropical Influenza Control Strategies for the Elderly

Completed·TTan Tock Seng Hospital·Phase 4·NCT02655874·200 enrolled

Influenza Vaccine in Lung Transplant Patients - Seroprotection

Completed·UUniversity of Wisconsin, Madison··NCT04531657·79 enrolled

Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults

Completed·VVanderbilt University··NCT02401893·510 enrolled

Influenza Vaccine in Lung Transplant Patients - T Cells

Completed·UUniversity of Wisconsin, Madison··NCT04533061·24 enrolled

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

Completed·RRobert J. Pignolo·Phase 2·NCT04176133·61 enrolled

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

Terminated· Gilead logo

Gilead··NCT03701438·2 enrolled

Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

Completed·AAbbott Biologicals·Phase 2·NCT01013675·622 enrolled

Beta-glucan and Immune Response to Influenza Vaccine

Completed·UUniversity of Florida·Phase 2·NCT05074303·78 enrolled

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

Completed·BButantan Institute·Phase 4·NCT01693380·1,742 enrolled

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

Completed·IInsel Gruppe AG, University Hospital Bern··NCT06738082·147 enrolled

Immune Response to Influenza Vaccine in ESRD Patients

Completed·MMahidol University·N/A·NCT04122222·60 enrolled

Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults

Completed·RRebecca Cox·Phase 1·NCT00868218·60 enrolled

Maternal Determinants of Immunity to Influenza

Completed·—·Phase 4·NCT06716567·109 enrolled

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

Completed·NNorthwestern University··NCT02623075·19 enrolled

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02519855·882 enrolled

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

Unknown status·CCenter for Human Reproduction·Phase 4·NCT02946177·126 enrolled

The Effect of Rituximab on the Humoral Response to Influenza Vaccine

Terminated·TTel-Aviv Sourasky Medical Center·N/A·NCT00466037·64 enrolled

Intradermal Trivalent Influenza Vaccine With Imiquimod

Completed·TThe University of Hong Kong·N/A·NCT01508884·93 enrolled

Duration of Immune Response to Influenza Vaccination in Patients With RA

Completed·BBassett Healthcare·Phase 4·NCT02311855·87 enrolled

Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy

Completed·OOttawa Hospital Research Institute·Phase 1·NCT02998736·28 enrolled

Field Trial of Maternal Influenza Immunization in Asia

Completed·—·Phase 3·NCT01034254·3,693 enrolled

Inactivated Influenza Via Jet Injection

Completed·PPharmaJet, Inc.·Phase 4·NCT02290691·985 enrolled

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects

Completed· Novartis logo

Novartis·Phase 2·NCT00918268·130 enrolled

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Completed· Moderna logo

Moderna·Phase 2·NCT06864143·1,320 enrolled

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Completed·CChina National Biotec Group Company Limited·Phase 4·NCT04091880·1,134 enrolled

Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine

Completed·AAbbott Biologicals·Phase 3·NCT00999206·3,138 enrolled

Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines

Active, not recruiting·—·Phase 4·NCT06091410·62 enrolled

Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine

Completed·UUniversity of Wisconsin, Madison··NCT05584735·46 enrolled

Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy

Unknown status·SSungkyunkwan University··NCT04579822·300,000 enrolled

Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route

Completed·IInternational Vaccine Institute·Phase 1·NCT01488188·40 enrolled

Influenza Vaccine in Lung Transplant Patients - Antibody

Completed·UUniversity of Wisconsin, Madison··NCT04533139·122 enrolled

Optimizing Influenza Vaccination in Surgical Oncology Patients

Unknown status·SStony Brook University·Phase 4·NCT01698177·204 enrolled

Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.

Completed· Novartis logo

Novartis·Phase 2·NCT00316615·100 enrolled

Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine

Completed·RResearch Institute for Biological Safety Problems·Phase 3·NCT03572491·2,000 enrolled

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines

Unknown status·NNational Centre for Epidemiology, Hungary·Phase 4·NCT01119157·85 enrolled

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Completed· Moderna logo

Moderna·Phase 3·NCT06097273·8,061 enrolled

Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial

Unknown status·TTan Tock Seng Hospital··NCT03399357·240 enrolled

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

Completed· GSK logo

GSK·Phase 3·NCT00380211·660 enrolled

The Immunogenicity of Intradermal Influenza Vaccination in Hemodialysis Patients

Completed·SShiraz University of Medical Sciences·Phase 2/3·NCT01273974·130 enrolled

Phase 1b Influenza Vaccine Study in Healthy Subjects

Completed·PPepTcell Limited·Phase 1·NCT01181336·48 enrolled

Intradermal Influenza Vaccine in the Young

Completed·TThe University of Hong Kong·Phase 3·NCT02103023·160 enrolled

Influenza Vaccine Challenge Study in Healthy Subjects

Completed·PPepTcell Limited·Phase 1·NCT01226758·32 enrolled

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Completed·AAlachua Government Services, Inc.·Phase 1/2·NCT00895544·231 enrolled

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Completed·AAdimmune Corporation·Phase 4·NCT01752881·130 enrolled

Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine

Completed·SSt. Petersburg Research Institute of Vaccines and Sera·Phase 2/3·NCT05869201·450 enrolled

Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)

Completed· Novartis logo

Novartis·Phase 3·NCT00310648·600 enrolled

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

Completed·NNovavax·Phase 2·NCT05519839·1,579 enrolled

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Terminated·—·Phase 2·NCT00596336·24 enrolled

Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis

Completed·—·Phase 4·NCT02831608·2,571 enrolled

Covid-19 and Influenza Oral Vaccine Study

Recruiting·VVaxine Pty Ltd·Phase 1·NCT06355232·100 enrolled

HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia

Completed·FFederico Martinón Torres·Phase 4·NCT06141655·134,476 enrolled

Effect of Influenza Vaccination on IVF Outcomes - IVF

Unknown status·CCenter for Human Reproduction·Phase 4·NCT02947217·238 enrolled

Safety and Immunogenicity Study of Intramuscular CCS/C-adjuvanted Influenza Vaccine in Elderly

Completed·NNasVax Ltd·Phase 2·NCT00915187·130 enrolled

A Randomized, Double-blind, Active-controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated (High Dose) in Adults Aged 60 Years and Older

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 1·NCT07737106·50 enrolled

Inflammatory Response2 trials

The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial

Completed·HHealth Sciences North Research Institute·Phase 4·NCT02565277·30 enrolled

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE

Recruiting·RRegion Örebro County·Phase 4·NCT06336317·90 enrolled

Coronary Artery Disease2 trials

The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases

Completed·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT00607217·360 enrolled

The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases

Completed·SShahid Beheshti University of Medical Sciences·Phase 2/3·NCT00607178·300 enrolled

Multiple Sclerosis2 trials

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

Completed· Roche logo

Roche·Phase 3·NCT02545868·102 enrolled

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Completed· Sanofi logo

Sanofi·Phase 2·NCT01403376·128 enrolled

Immune Response2 trials

Bone Marrow and Peripheral Blood Immune Responses Study

Recruiting·EEmory University·Phase 4·NCT05616546·90 enrolled

Immune Responses in Health Care Personnel

Recruiting·FFinnish Institute for Health and Welfare··NCT03323112·150 enrolled

26 more indications

Immunogenicity2 trials

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Completed· Pfizer logo

Pfizer·Phase 3·NCT04526574·1,796 enrolled

Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children

Unknown status·SSt. Petersburg Research Institute of Vaccines and Sera·Phase 3·NCT05739474·948 enrolled

Experimental1 trial

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT05294588·65 enrolled

Pancreatic Cancer1 trial

Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.

Terminated·HHerlev Hospital·Phase 2·NCT05116917·19 enrolled

Acute Coronary Syndrome1 trial

Influenza Vaccination After Acute Coronary Syndrome

Recruiting·TTongji Hospital·N/A·NCT07259252·6,620 enrolled

Colorectal Cancer1 trial

Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer

Not yet recruiting·ZZealand University Hospital·Phase 2·NCT05909423·21 enrolled

Hematopoietic Stem Cell Transplantation1 trial

Studies of the Immune Response to Vaccination After Hematopoietic Stem Cell Transplantation

Completed·UUniversity of California, San Francisco··NCT01581164·12 enrolled

Sarcoidosis1 trial

Antibody Response to Influenza Vaccine in Patients With Sarcoidosis

Completed·SShahid Beheshti University of Medical Sciences··NCT00828828·49 enrolled

Stroke1 trial

Preventing Stroke Triggers in Children With Sickle Cell Anaemia in Mulago Hospital, Kampala (PREST ): a Randomized Control Trial

Unknown status·MMakerere University·Phase 2/3·NCT03666806·150 enrolled

Heart Failure1 trial

VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT02268500·48 enrolled

Mood Disorder1 trial

Influenza Challenge in Mood Disorders

Terminated·LLaureate Institute for Brain Research, Inc.·N/A·NCT02415166·6 enrolled

Obstructive Sleep Apnea1 trial

Immunological Consequences of Obstructive Sleep Apnea

Completed·UUniversity of Wisconsin, Madison·N/A·NCT00214071·30 enrolled

Vaccination1 trial

Vaccination Efficacy With Metformin in Older Adults

Completed·UUConn Health·Phase 1·NCT03996538·26 enrolled

Breast Cancer1 trial

VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)

Completed·UUniversity of Miami·Phase 4·NCT03955991·109 enrolled

Tyrosine Kinase Inhibitor1 trial

Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor

Completed·RRadboud University Medical Center··NCT00979381·75 enrolled

Pneumococcal Vaccines1 trial

Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.

Unknown status·SSungkyunkwan University··NCT04551248·1,000,000 enrolled

Heart Disease1 trial

Risk Reduction in Coronary Heart Disease

Completed·SSorlandet Hospital HF·N/A·NCT00679237·1,600 enrolled

Scleroderma1 trial

Influenza Vaccination in Patients With Scleroderma

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT01002508·80 enrolled

Herpes Zoster1 trial

Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)

Completed·RRadboud University Medical Center·Phase 2·NCT05082688·148 enrolled

Elderly1 trial

Immune Benefits of WGP in Elderly

Completed·SSociété des Produits Nestlé (SPN)·N/A·NCT02262091·150 enrolled

Social Behavior1 trial

Body and Social Behavior

Completed·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT05654441·104 enrolled

Metabolic Syndrome1 trial

Impact of Metabolic Syndrome on Flu Vaccine Efficacy

Terminated·RRockefeller University·N/A·NCT02653495·17 enrolled

Phase 21 trial

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Terminated·NNovavax·Phase 2·NCT03658629·1,375 enrolled

Chronic Lymphocytic Leukemia1 trial

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01924169·3 enrolled

Hepatitis B1 trial

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

Completed·—··NCT03056924·173 enrolled

Clinical Trial1 trial

A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd··NCT07071701·19,267 enrolled

Rheumatologic Disorder1 trial

Booster Vaccine Strategy to Improve Serologic Responses to Influenza Vaccination in Children With Rheumatic Diseases and Inflammatory Bowel Disease Who Are Receiving Immunosuppressive Therapies

Completed·SStony Brook University·Phase 2·NCT03277703·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 106 trial records for Influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Novartis

Influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2028

Q1 2029

Trials by Indication[1]

Influenza71 trials

Inflammatory Response2 trials

Coronary Artery Disease2 trials

Multiple Sclerosis2 trials

Immune Response2 trials

Immunogenicity2 trials

Experimental1 trial

Pancreatic Cancer1 trial

Acute Coronary Syndrome1 trial

Colorectal Cancer1 trial

Hematopoietic Stem Cell Transplantation1 trial

Sarcoidosis1 trial

Stroke1 trial

Heart Failure1 trial

Mood Disorder1 trial

Obstructive Sleep Apnea1 trial

Vaccination1 trial

Breast Cancer1 trial

Tyrosine Kinase Inhibitor1 trial

Pneumococcal Vaccines1 trial

Heart Disease1 trial

Scleroderma1 trial

Herpes Zoster1 trial

Elderly1 trial

Social Behavior1 trial

Metabolic Syndrome1 trial

Phase 21 trial

Chronic Lymphocytic Leukemia1 trial

Hepatitis B1 trial

Clinical Trial1 trial

Rheumatologic Disorder1 trial

References

Drug Info

Quick Facts

Related News